As midnight on June 3 approaches, many plans face considerable uncertainties relating to the Inflation Reduction Act’s benefit redesign, Medicare Prescription Payment Plan, and changes from the Advance Notice. In fact, uncertainty is driven not just by how the market and enrollees may react to the Inflation Reduction Act, but the possible actions by pharmaceutical manufacturers and pharmacies. We continue our Medicare Webinar series by highlighting potential reactions and strategies from the perspective of Medicare Advantage Organizations and other industry stakeholders.
